Amag Pharmaceuticals downgraded to Underweight from Neutral at Piper Jaffray

Piper Jaffray analyst Christoper Raymond downgraded Amag Pharmaceuticals to Underweight from Neutral with a price target of $6, down from $9.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.